Novavax, Inc. (NVAX) — closed signal from February 10, 2026
Target reached Published before the outcome was known, scored automatically when the window closed on May 11, 2026.
Predicted vs. what happened
What happened
Reached its target in 16 days.
The thesis — published February 10, 2026
This is a short-term trade based on Pfizer licensing Novavax's adjuvant (Matrix-M) for vaccines. If timing and payment details become clearer, people may expect more sales and the stock could jump. But sales are forecast to fall sharply, and views can reverse quickly. Only buy on weakness near the stated zone and sell into big news-driven rallies; funding risk remains.
Primary drivers
- Pfizer deal gives a clear event to watch
- Clearer revenue and milestone timing could lift expectations
- Guidance or demand updates will move sentiment a lot
- Turnaround hopes can trigger sudden squeezes
How it played out
NVAX: target reached in 16 days
Lyra published NVAX at $8.78 on 2026-02-10 as a short-term trade with 30% expected growth. The thesis pointed to Pfizer licensing Novavax's Matrix-M adjuvant, possible clarity on revenue and milestone timing, guidance or demand updates, and turnaround hopes that could trigger sudden squeezes. It also noted that sales were forecast to fall sharply and that funding risk remained.
Inside the window, NVAX reached a peak of $11.97 on 2026-02-26, above the $11.41 target. The target was reached in 16 days. The peak gain was 36.3%. By 2026-05-11, the stock ended at $9.50. The thesis played out.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.